Ikuo Konishi

Ikuo Konishi

Auto-generated profile, based on publicly available information

Ikuo Konishi

Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2017 in Diagnostics
Verified
Journal Article
Open access
PDF file
Masafumi KoshiyamaMasafumi Koshiyama
Masafumi Koshiyama
Noriomi MatsumuraNoriomi Matsumura
Noriomi Matsumura
IKIkuo Konishi
Ikuo Konishi
Ovarian cancer is the foremost cause of gynecological cancer death in the developed world, as it is usually diagnosed at an advanced stage. In this paper we discuss current issues, the efficacy and problems associated with ovarian cancer screening, and compare the characteristics of ovarian cancer subtypes. There are two types of ovarian cancer: Type I carcinomas, which are slow-growing, indolent neoplasms thought to arise from a precursor lesion, which are relatively common in Asia; and Type II carcinomas, which are clinically aggressive neoplasms that can develop de novo from serous tubal intraepithelial carcinomas (STIC) and/or ovarian surface epithelium and are common in Europe and the USA. One of the most famous studies on the subject reported that annual screening using CA125/transvaginal sonography (TVS) did not reduce the ovarian cancer mortality rate in the USA. In contrast, a recent study in the UK showed an overall average mortality reduction of 20% in the screening group. Another two studies further reported that the screening was associated with decreased stage at detection. Theoretically, annual screening using CA125/TVS could easily detect precursor lesions and could be more effective in Asia than in Europe and the USA. The detection of Type II ovarian carcinoma at an early stage remains an unresolved issue. The resolving power of CA125 or TVS screening alone is unlikely to be successful at resolving STICs. Biomarkers for the early detection of Type II carcinomas such as STICs need to be developed.

18 October 2012 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
RHRuby Huang
Ruby Huang
GCGeng Bo Chen
Geng Bo Chen
Noriomi MatsumuraNoriomi Matsumura
Noriomi Matsumura
HLHung-Cheng Lai
Hung-Cheng Lai
SMSeiichi Mori
Seiichi Mori
LGLiang Goh
Liang Goh
Background: Epithelial ovarian cancer is characterized by multiple genomic alterations; most are passenger alterations which do not confer tumor growth. Like many cancers, it is a heterogeneous disease and can be broadly categorized into 4 main histotypes of clear cell, endometrioid, mucinous, and serous. To date, histotype-specific copy number alterations have been difficult to elucidate. The difficulty lies in having sufficient sample size in each histotype for statistical analyses. Methods: To dissect the heterogeneity of ovarian cancer and identify histotype-specific alterations, we used an in silico hypothesis-driven approach on multiple datasets of epithelial ovarian cancer. Results: In concordance with previous studies on global copy number alterations landscape, the study showed similar alterations. However, when the landscape was de-convoluted into histotypes, distinct alterations were observed. We report here significant histotype-specific copy number alterations in ovarian cancer and showed that there is genomic diversity amongst the histotypes. 76 cancer genes were found to be significantly altered with several as potential copy number drivers, including ERBB2 in mucinous, and TPM3 in endometrioid histotypes. ERBB2 was found to have preferential alterations, where it was amplified in mucinous (28.6%) but deleted in serous tumors (15.1%). Validation of ERBB2 expression showed significant correlation with microarray data (p=0.007). There also appeared to be reciprocal relationship between KRAS mutation and copy number alterations. In mucinous tumors where KRAS mutation is common, the gene was not significantly altered. However, KRAS was significantly amplified in serous tumors where mutations are rare in high grade tumors. Conclusions: The study demonstrates that the copy number landscape is specific to the histotypes and identification of these alterations can pave the way for targeted drug therapy specific to the histotypes.

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JHJunzo Hamanishi
Junzo Hamanishi
MMMasaki Mandai
Masaki Mandai
TITakafumi Ikeda
Takafumi Ikeda
MMManabu Minami
Manabu Minami
AKAtsushi Kawaguchi
Atsushi Kawaguchi
IKIkuo Konishi
Ikuo Konishi
5511 Background: Programmed death-1 (PD-1) is a co-inhibitory receptor expressed on activated T cells which regulates antitumor immunity. Nivolumab is a fully-humanized IgG4 that blocks the engagement of PD-1 by PD-1 ligands. Here we report the first trial for clinical application of nivolumab in ovarian cancer patients. Methods: Nivolumab was administered every 2 weeks to patients with advanced or relapsed, platinum–resistant ovarian cancer, at the doses of 1 or 3 mg/kg during two cohort examination (10 patients each). The phase II efficacy trial defined 1st endpoint of response rate, and second endpoints of safety, and disease control rate. Patients receivednivolumab up to 6 cycles (4 doses/cycle) of treatment or until PD or disease progression. Response rate was assessed by RECIST v1.1, and adverse events were evaluated by CTCAE v4.0. The data were cut-off on January 1, 2014. Results: Fifteen patients were treated with nivolumab (1 mg/kg: n=10, 3mg/kg: n=5), and evaluated. Median duration of therapy was 14 wks. There was one patient who had severe adverse drug reaction with fever, disorientation and gait disturbance. Clinical response rates were shown in Table. At the time of data cut off, one of the three partial responders had responses for 5 months, and the other two were on study with response for 4 and 10 months. Conclusions:Nivolumab at 1 mg/kg cohort is well tolerated and has encouraging clinical efficacy for advanced or relapsed, platinum-resistant ovarian cancer patients. 3 mg/kg cohort is now under investigation. Clinical trial information: UMIN000005714.

1 October 1991 in Endocrinology
Verified
Journal Article
Closed access
TIToshiko Iwai
Toshiko Iwai
SFShingo Fujii
Shingo Fujii
YNYoshihiko Nanbu
Yoshihiko Nanbu
HNHirofumi Nonogaki
Hirofumi Nonogaki
IKIkuo Konishi
Ikuo Konishi
HOHitoshi Okamura
Hitoshi Okamura
To investigate whether LH/human CG (hCG) or progesterone acts as a regulator of estrogen receptors (ER) and progesterone receptors (PR) in granulosa cells, we studied the immunohistochemical expression of both ER and PR in the ovary and the uterus of mature rabbits, during the induction of ovulation by FSH followed by administration of hCG, progesterone, or a progesterone antagonist (RU486) and hCG. Granulosa ceils pretreated with FSH for 3 days showed ER staining, but negligible PR staining. The staining pattern for ER and PR changed in animals pretreated with FSH followed by hCG injection; by 6 h after hCG injection, we observed the disappearance of ER and the appearance of PR, and by 3 days after hCG injection, we observed the reappearance of ER and the disappearance of PR, However, the expression of ER and PR in the granulosa cells of animals pretreated with FSH followed by progesterone administration instead of hCG was almost the same as that of animals pretreated with FSH alone. In addition, the expression of ER and PR in the granulosa cells of animals pretreated with FSH followed by RU486 and hCG was almost the same as that of animals pretreated with FSH followed by hCG administration. The uterine glandular epithelium, in contrast, began to show decreased appearance of ER and PR by 48 h after hCG injection, and we observed the disappearance of both receptors by 3 days after hCG administration. These results suggest that the expression of ER and PR in granulosa cells is not regulated by the action of progesterone, but by that of LH/ hCG. (Endocrinology129: 1840–1843,1991)

1 January 2014 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
NMNobuko Morisawa
Nobuko Morisawa
AKAki Kido
Aki Kido
MKMasako Kataoka
Masako Kataoka
SMSachiko Minamiguchi
Sachiko Minamiguchi
IKIkuo Konishi
Ikuo Konishi
KTKaori Togashi
Kaori Togashi
The purpose of the study was to investigate the magnetic resonance imaging findings of decidualized endometriotic cysts in comparison with endometriotic cysts associated with ovarian cancers. Eighteen decidualized endometriotic cysts and 24 ovarian cancers were retrospectively assessed on height, signal intensity of the solid component on T2- and diffusion-weighted imaging, apparent diffusion coefficient value of the solid component, size of the lesion, and signal intensity of the intracystic fluid on T1-weighted imaging. The heights of the solid components in the decidualized endometriotic cysts were inferior to 11.1 mm, significantly lower compared with the ovarian cancers. Similarly, decidualized tissues showed significantly higher signals on T2-weighted imaging and higher apparent diffusion coefficient values compared with ovarian cancers but not on diffusion-weighted imaging. The decidualized endometriotic cysts were also significantly smaller. Intracystic fluids showed higher signal in the decidualized endometriotic cysts compared with ovarian cancers on T1-weighted imaging. In pregnant subjects, the presence of endometriotic cysts with low-height solid component showing high signal intensities on T2-weighted imaging is highly indicative of decidualization.

22 August 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
IKIkuo Konishi
Ikuo Konishi
KAKaoru Abiko
Kaoru Abiko
Takuma HayashiTakuma Hayashi
Takuma Hayashi
KYKoji Yamanoi
Koji Yamanoi
RMRyusuke Murakami
Ryusuke Murakami
KRKyoto Study Group for Ovarian Cancer Research
Kyoto Study Group for Ovarian Cancer Research
Konishi I, et al. J Gynecol Oncol. 2022 Aug;33(5):e83. https://doi.org/10.3802/jgo.2022.33.e83